Table 2.
Correlation between mutation profile and clinicopathological features in 461 patients with metastatic colorectal cancer.
| Clinicopathological features | n | KRAS | Status | BRAF | Status | NRAS | Status | All wild-type | Any mutation | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wild-type (n = 260, %) | Mutation (n = 201, %) | P | Wild-type (n = 435, %) | Mutation (n = 26, %) | P | Wild-type (n = 448, %) | Mutation (n = 13, %) | P | (n = 231, %) | (n = 230, %) | P | ||
| Gender | |||||||||||||
| Male | 250 | 143 (57.2) | 107 (42.8) | 0.706 | 241 (96.4) | 9 (3.6) | 0.039 | 245 (98.0) | 5 (2.0) | 0.247 | 133 (53.2) | 117 (46.8) | 0.148 |
| Female | 211 | 117 (55.5) | 94 (44.5) | 194 (91.9) | 17 (8.1) | 203 (96.2) | 8 (3.8) | 98 (46.4) | 113 (53.6) | ||||
| Age, years | |||||||||||||
| <65 | 241 | 140 (58.1) | 101 (41.9) | 0.443 | 231 (95.9) | 10 (4.1) | 0.147 | 237 (98.3) | 4 (1.7) | 0.115 | 131 (54.4) | 110 (45.6) | 0.056 |
| ≥65 | 220 | 120 (54.5) | 100 (45.5) | 204 (92.7) | 16 (7.3) | 211 (95.9) | 9 (4.1) | 100 (45.5) | 120 (54.5) | ||||
| Tumor location | |||||||||||||
| Left colon | 209 | 123 (58.9) | 86 (41.1) | 0.509 | 193 (92.3) | 16 (7.7) | 0.001 | 205 (98.1) | 4 (1.9) | 0.097 | 105 (50.2) | 104 (49.8) | 0.565 |
| Right colon | 55 | 32 (58.2) | 23 (41.8) | 48 (87.3) | 7 (12.7) | 51 (92.7) | 4 (7.3) | 24 (43.6) | 31 (56.4) | ||||
| Rectum | 197 | 105 (53.3) | 92 (46.7) | 194 (98.5) | 3 (1.5) | 192 (97.5) | 5 (2.5) | 102 (51.8) | 95 (48.2) | ||||
| Primary tumor size | |||||||||||||
| <5 cm | 381 | 216 (56.7) | 165 (43.3) | 0.781 | 357 (93.7) | 24 (6.3) | 0.181 | 368 (96.6) | 13 (3.4) | 0.094 | 189 (49.6) | 192 (50.4) | 0.638 |
| ≥5 cm | 80 | 44 (55.0) | 36 (45.0) | 78 (97.5) | 2 (2.5) | 80 (100.0) | 0 (0.0) | 42 (52.5) | 38 (47.5) | ||||
| Differentiation | |||||||||||||
| Well/moderate | 289 | 166 (57.4) | 123 (42.6) | 0.559 | 269 (93.1) | 20 (6.9) | 0.122 | 278 (96.2) | 11 (3.8) | 0.097 | 142 (49.1) | 147 (50.9) | 0.588 |
| Poor | 172 | 94 (54.7) | 78 (45.3) | 166 (96.5) | 6 (3.5) | 170 (98.8) | 2 (1.2) | 89 (51.7) | 83 (48.3) | ||||
| Histological type | |||||||||||||
| Papillary/tubular adenocarcinoma | 380 | 211 (55.5) | 169 (44.5) | 0.413 | 358 (94.2) | 22 (5.8) | 0.763 | 369 (97.1) | 11 (2.9) | 0.834 | 186 (48.9) | 194 (51.1) | 0.280 |
| Mucinous/signet ring cell | 81 | 49 (60.5) | 32 (39.5) | 77 (95.1) | 4 (4.9) | 79 (97.5) | 2 (2.5) | 45 (55.6) | 36 (44.4) | ||||
| Depth of invasion | |||||||||||||
| T1 | 2 | 0 (0.0) | 2 (100.0) | 0.266 | 2 (100.0) | 0 (0.0) | 0.557 | 2 (100.0) | 0 (0.0) | 0.53 | 0 (0.0) | 2 (100.0) | 0.300 |
| T2 | 30 | 14 (46.7) | 10 (53.3) | 28 (93.3) | 2 (6.7) | 30 (100.0) | 0 (0.0) | 12 (40.0) | 18 (60.0) | ||||
| T3 | 347 | 158 (57.6) | 126 (42.4) | 325 (93.7) | 22 (6.3) | 335 (96.5) | 12 (3.5) | 175 (50.4) | 172 (49.6) | ||||
| T4 | 82 | 38 (56.1) | 26 (43.9) | 80 (97.6) | 2 (2.3) | 81 (98.8) | 1 (1.2) | 44 (53.7) | 38 (46.3) | ||||
| Nodal stage | |||||||||||||
| N0 | 32 | 15 (46.9) | 17 (53.1) | 0.143 | 32 (100.0) | 0 (0.0) | 0.319 | 32 (100.0) | 0 (0.0) | 0.680 | 15 (46.9) | 17 (53.1) | 0.224 |
| N1 | 285 | 171 (60.0) | 114 (40.0) | 265 (93.0) | 20 (7.0) | 276 (96.8) | 9 (3.2) | 150 (46.9) | 135 (53.1) | ||||
| N2a | 95 | 52 (54.7) | 43 (45.3) | 91 (95.8) | 4 (4.2) | 93 (97.9) | 2 (2.1) | 48 (50.5) | 47 (49.5) | ||||
| N2b | 49 | 22 (44.9) | 27 (55.1) | 47 (95.9) | 2 (4.1) | 47 (95.9) | 2 (4.1) | 18 (36.7) | 31 (63.3) | ||||
| Metastatic site | |||||||||||||
| Brain | 19 | 4 (21.1) | 15 (78.9) | 0.011 | 17 (89.5) | 2 (10.5) | 0.172 | 19 (100.0) | 0 (0.0) | 0317 | 3 (15.8) | 16 (84.2) | 0.002 |
| Lung | 121 | 66 (54.5) | 55 (45.5) | 112 (92.6) | 9 (7.4) | 115 (95.0) | 6 (5.0) | 53 (43.8) | 68 (56.2) | ||||
| Liver | 233 | 136 (58.4) | 97 (41.6) | 219 (94.0) | 14 (6.0) | 227 (97.4) | 6 (2.6) | 122 (52.4) | 111 (47.6) | ||||
| Others | 88 | 54 (61.4) | 34 (38.6) | 87 (98.9) | 1 (1.1) | 87 (98.9) | 1 (1.1) | 53 (60.2) | 35 (39.8) | ||||
| COX-2 expression | |||||||||||||
| Negative | 128 | 63 (49.2) | 65 (50.8) | 0.054 | 123 (96.1) | 5 (3.9) | 0.317 | 124 (96.9) | 4 (3.1) | 0.806 | 58 (45.3) | 70 (54.7) | 0.202 |
| Positive | 333 | 197 (59.2) | 136 (40.8) | 312 (93.7) | 21 (6.3) | 324 (97.3) | 9 (2.7) | 173 (52.0) | 160 (48.0) | ||||
| C-MET expression | |||||||||||||
| Negative/weak | 178 | 109 (61.2) | 69 (38.8) | 0.097 | 171 (96.1) | 7 (3.9) | 0.208 | 171 (96.1) | 7 (3.9) | 0.252 | 99 (55.6) | 79 (44.4) | 0.061 |
| Moderate/strong | 283 | 151 (53.4) | 132 (46.6) | 264 (93.3) | 19 (6.7) | 277 (97.9) | 6 (2.1) | 132 (46.6) | 151 (53.4) | ||||
| Initial CEA (ng/mL) | |||||||||||||
| <20 | 70 | 54 (77.1) | 16 (22.9) | <0.001 | 68 (97.1) | 2 (2.9) | 0.273 | 70 (100.0) | 0 (0.0) | 0.122 | 52 (74.3) | 18 (25.7) | <0.001 |
| ≥20 | 391 | 206 (52.7) | 185 (47.3) | 367 (93.9) | 24 (6.1) | 378 (96.7) | 13 (3.3) | 179 (45.8) | 212 (54.2) | ||||
| MSI | |||||||||||||
| MSI-H | 30 | 20 (66.7) | 10 (33.3) | 0.241 | 26 (86.7) | 4 (13.3) | 0.059 | 30 (100.0) | 0 (0.0) | 0.335 | 16 (53.3) | 14 (46.7) | 0.715 |
| MSI-L/MSS | 431 | 240 (55.7) | 191 (44.3) | 409 (94.9) | 22 (5.1) | 418 (97.0) | 13 (3.0) | 215 (49.9) | 216 (50.1) | ||||
COX-2 = cyclooxygenase-2; CEA = carcinoembryonic antigen; C-MET = mesenchymal-epithelial transition factor; MSI = microsatellite instability; MSI-H = MSI-high; MSI-L = MSI-low; MSS = microsatellite stability.